Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hylatopic Plus is a topical skin barrier repair therapy (BRT) used for the management of atopic dermatitis and other skin conditions characterized by a compromised skin barrier. It is formulated as a cream or lotion containing a blend of lipids (such as ceramides and fatty acids) and humectants (including sodium hyaluronate) designed to restore the skin's natural barrier function, reduce transepidermal water loss (TEWL), and improve hydration. Originally developed by PreCision Dermatology, the product was acquired by Valeant Pharmaceuticals in 2014 and subsequently sold to Encore Dermatology in 2016. It is often utilized as a monotherapy or in conjunction with topical corticosteroids to manage mild to moderate atopic dermatitis symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hylatopic Plus (PreCision Dermatology, Inc.).